info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)
Certified Global Research Member
Esomar23 wcrc
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Vasomotor Symptoms Companies

Addressing women's health, Vasomotor Symptoms companies focus on solutions for menopausal symptoms. Through research and innovation, they offer therapies to alleviate vasomotor symptoms like hot flashes and night sweats, enhancing the quality of life for women transitioning through menopause.

Top Industry Leaders in the Vasomotor Symptoms Market

Vasomotor Symptoms Key Companies

 


Latest Vasomotor Symptoms Companies Update:

Astellas' VEOZATM Received EU approval in December 2023 and US FDA approval in May 2023 for treating moderate to severe VMS due to menopause.First non-hormonal neurokinin 3 (NK3) receptor antagonist approved for VMS, offering a new option for women seeking non-hormonal treatment.


Abbott's Upledity Launched in the US in November 2023 for moderate to severe VMS and other menopausal symptoms. Offers a new low-dose oral hormonal option for some women.


Therapeutics Unlimited's Zyla Received FDA approval in November 2023 for the treatment of menopausal symptoms, including VMS. Offers a new topical estrogen option for women seeking to avoid systemic treatments.


List of Vasomotor Symptoms Key companies in the market

  • Allergan (Ireland)

  • Pfizer Inc. (US)

  • Eli Lily and Company (US)

  • Novartis AG (Switzerland)

  • Emcure Pharmaceuticals Ltd (India)

  • Merck & Co.Inc. (US)

  • TherapeuticsMD Inc. (US)

  • Mithra Pharmaceuticals (Belgium)


Leading companies partner with us for data-driven Insights
clients
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.